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Background/Purpose: Sevelamer hydrochloride is a recently developed phosphate binder, which is a 
quaternary amine anion exchanger without calcium or aluminum. Sevelamer is effective in controlling hy-
perphosphatemia without increasing the calcium load in chronic hemodialysis (HD) patients. We investi-
gated whether sevelamer restored bone metabolism in chronic HD patients.
Methods: An 8-week, prospective, open-label, randomized study was conducted after a 2-week washout
period in chronic hyperphosphatemic HD patients. This study compared the effect of sevelamer on mark-
ers of bone turnover with that of calcium acetate, as stratified by baseline serum intact parathyroid hor-
mone (iPTH) level.
Results: There was no difference in the changes of serum phosphorus, calcium-phosphorus product and
serum iPTH between the sevelamer and the calcium acetate groups. However, more hypercalcemic events
(12%) were documented under calcium acetate treatment. In patients with hypoparathyroidism, calcium
acetate treatment decreased serum iPTH at the end of the study, while sevelamer did not. Increased serum
alkaline phosphatase levels were found among patients receiving sevelamer treatment compared with
those who received calcium acetate treatment. In those patients receiving sevelamer, the serum alkaline
phosphatase level was also positively correlated to the sevelamer dosage (r = 0.246, p = 0.013).
Conclusion: Sevelamer effectively reduces serum phosphorus with a lower incidence of hypercalcemic 
effects in HD patients. Sevelamer is an effective means of treatment for chronic hyperphosphatemic HD
patients, especially those with hypoparathyroidism.
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Hyperphosphatemia in hemodialysis (HD) pa-
tients is related to secondary hyperparathyroidism
and extraosseous calcification. Both hyperphos-
phatemia and secondary hyperparathyroidism play
a crucial role in the development of renal osteodys-
trophy in end-stage renal disease (ESRD) patients.
In clinical practice, hyperphosphatemia in HD pa-
tients is not adequately controlled by dietary phos-
phorus restriction and HD. Phosphate binders
have been routinely prescribed to reduce intestinal
absorption of phosphorus. Unfortunately, alu-
minum toxicity1,2 and significant hypercalcemia3,4
limit the usage of these agents. Calcium-containing
binders have been associated with arterial calcifi-
cation, which causes arterial stiffening and fur-
ther cardiovascular morbidity and mortality.5−9
In HD patients, higher than normal para-
thyroid hormone (PTH) levels are necessary to
stabilize mineral metabolism, increasing bone
turnover. However, approximately 64% of HD
patients suffer from low turnover bone disease.10
Hypoparathyroidism caused by the combination
treatment of vitamin D and calcium-based phos-
phate binders contributes to low turnover bone
disease, which is related to high mortality from
cardiovascular calcification.11,12
Sevelamer hydrochloride is a recently devel-
oped phosphate binder that is a quaternary amine
anion exchanger without calcium or aluminum.13
Several studies have shown that sevelamer reduces
serum phosphorus levels effectively in HD pa-
tients.13−18 However, the effect of sevelamer on
bone metabolism in the setting of uremic hypo-
parathyroidism and low turnover bone metabo-
lism needs more precise definition. Therefore, we
used intact parathyroid hormone (iPTH) and al-
kaline phosphatase (ALP) as biomarkers of bone
turnover to evaluate the influence of sevelamer
on bone metabolism in Taiwanese HD patients.
Materials and Methods
Ethics
This study was conducted in accordance with 
the ethical principles outlined in the Declaration
of Helsinki, Good Clinical Practice and appli-
cable regulatory requirements. We obtained ap-
proval for this study from the Institutional
Review Board of National Taiwan University
Hospital, Taipei, Taiwan. In addition, written
consent was obtained from all patients or their
next of kin.
Study population and data collection
This study was a single-center, open-label, random-
ized, parallel group trial to compare the efficacy
and safety of sevelamer and calcium acetate treat-
ment in HD patients. Patients who were older than
18 years of age, receiving stable regular HD for at
least 3 months and phosphate binders (either cal-
cium carbonate, calcium acetate, aluminum salts,
or sevelamer) for at least 1 month, were included if
hyperphosphatemia (serum phosphorus > 5.5 mg/
dL and ≤ 8.5 mg/dL) developed again after the 
2-week washout period. If patients were on vita-
min D replacement therapy, the dosage must have
been stable for at least 3 months prior to screening.
Patients were excluded if they had severe hypercal-
cemia (adjusted serum calcium > 11 mg/dL), un-
controlled blood pressure, poor heart function
(the New York Heart Association stage > 3), ab-
normal liver function (alanine transaminase or
aspartate aminotransferase level over 3 times the
upper limit of normal value), gastrointestinal
motility disorder, or malignancy during the
washout period. The baseline demography and
medical history of all the patients included in
the trial were reviewed. These patients started 
to take one, two, or three capsules of sevelamer
(800 mg), or tablets of calcium acetate (667 mg)
with meals three times a day, according to the level
of hyperphosphatemia after the washout period:
one tablet tid if the level was > 5.5 mg/dL and
≤ 6.5 mg/dL, two tablets tid if > 6.5 mg/dL and
≤ 7.5 mg/dL and three tablets if > 7.5 mg/dL 
and ≤ 8.5 mg/dL. At each subsequent 2-week in-
terval, the dosage was titrated gradually to achieve
the target level of serum phosphorus (3.5 mg/dL
to 5.5 mg/dL) and decreased or increased by one
tablet if serum phosphorus was < 3.5 mg/dL or
> 5.5 mg/dL, accordingly. Efficacy was evaluated
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on the basis of changes in serum phosphorus,
serum calcium, serum iPTH and serum ALP.
Hypercalcemic events were defined as adjusted
serum calcium levels greater than 11 mg/dL. Ad-
justed serum calcium was calculated using the
following equation:
Adjusted serum calcium (mg/dL)
= [4-albumin (g/dL)] × 0.8
+ calcium (mg/dL)
Measurements of serum iPTH and ALP
Serum iPTH was measured by IMMULITE 2000
second-generation iPTH assay (the Diagnostics
Product Corp., Los Angeles, CA, USA), a solid-
phase two-site chemiluminescent immunoassay
with a monoclonal mouse capture antibody and a
polyclonal goat signal antibody conjugated to ALP.
The solid phase was a polystyrene bead coated
with an affinity-purified murine monoclonal anti-
PTH C-terminal (44–84) antibody, and had no de-
tectable cross-reactivity to the N-terminal region.
Conversely, the ALP-conjugated affinity-purified
goat polyclonal anti-PTH N-terminal (1–34) anti-
body recognized only the N-terminal region, and
had no detectable cross-reactivity to C-terminal
or mid-molecule regions. Accordingly, the assay,
which required binding by both enzyme-labeled
and solid-phase antibodies, was able to recognize
only iPTH and very large PTH fragments, nearly as
long as iPTH itself. One such fragment, N-terminal-
truncated PTH (7–84), exhibited cross-reactivity
(44.8%) in this assay; the ratio of the recovery of
synthetic 1–84 and 7–84 PTH in this assay was
0.57 and indicated that the assay cross-reacted
with 7–84 PTH less than with 1–84 PTH. The
intra-assay coefficient of variation was 5.7% and
the inter-assay coefficient of variation was 6.3%.
The detection limit was 3.0 ng/L.
Serum ALP was measured enzymatically with
an automatic multi-purpose analyzer (TBA200 FR,
Toshiba Medical Products, Tokyo, Japan), using
the para-nitrophenyl phosphate method with the
2-ethylaminoethanol buffer (Denka Seiken, Tokyo,
Japan), with intra- and inter-assay, 1.00% and
0.82%, respectively.
Statistical analysis
Data were analyzed using intension-to-treat analy-
sis. All statistical analyses were based on two-sided
hypothesis tests with a significance level of 0.05.
For continuous data, the mean and 95% confi-
dence interval of change from baseline in each
treatment group were computed and the differ-
ence between the two treatment groups was ana-
lyzed by analysis of covariance with baseline value
as the covariate. The differences of the mean and
95% confidence interval of change from baseline
between the two treatment groups were also
computed. We used non-parametric Wilcoxon
matched-pairs signed ranks test in subgroup an-
alysis because the patient number was small.
Discrete variables (i.e. response to treatment) were
presented as a percentage and analyzed using 
χ2 test. The number and percentage of patients
attaining a response and corresponding 95% con-
fidence interval were also presented. To assess
safety, the incidence of adverse events (AE) was
compared using Fisher’s exact test. All statistical
analyses were performed using SPSS version 14.0
(SPSS Inc., Chicago, IL, USA) and STATA statistical
software, release 9.0 (StataCorp. College Station,
TX, USA).
Results
Demographics, baseline laboratory comparisons
and AEs
A total of 52 patients with ESRD on maintenance
HD were enrolled after screening for hyperphos-
phatemia. Twenty-six patients were randomized to
the sevelamer group and calcium acetate group.
The characteristics of each group were compared
and no significant differences were found (Table 1).
Of the 52 patients who were randomized into the
treatment phase, a total of 43 patients completed
the study (Figure 1). The most commonly reported
AEs among sevelamer treated patients were flatu-
lence (4 patients, 15.4%) and gastrointestinal
upset (2 patients, 7.7%). Among calcium acetate
treated patients, the most commonly reported AEs
were constipation (6 patients, 23.1%), nausea 
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Table 1. Patient characteristics*
Parameter Calcium acetate (n = 26) Sevelamer (n = 26) p†
Age (yr) 56.0 (13.6) 58.5 (10.3) 0.453
Sex, male:female 18:8 12:14 0.055
Duration of dialysis (yr) 2.6 ± 2.6 4.6 ± 5.2 0.088
Primary cause of ESRD 0.581
Hypertension 1 (4.0) 0 (0)
Diabetes 7 (26.9) 11 (42.3)
PCKD 1 (4.0) 1 (3.8)
Others 17 (68.0) 14 (53.8)
Kt/V 1.4 (0.3) 1.4 (0.3) 0.255
Body weight (kg) 64.9 ± 15.7 60.2 ± 11.2 0.214
Pre-study phosphate binder 1.000
Aluminum 3 (11.5) 4 (15.4)
Calcium-containing 23 (88.5) 22 (84.6)
Parathyroidectomy 1.000
Yes 2 (7.7) 2 (7.7)
Kidney transplant 0.491
Yes 0 (0) 2 (7.7)
Baseline iPTH (pg/mL) 0.460
< 150 8 (15.4) 8 (15.4)
150–300 9 (17.3) 6 (11.5)
> 300 9 (17.3) 12 (23.1)
Dialysate calcium concentration (mmol/L) 0.129
2.5 11 (42.3) 10 (38.5)
3.0 11 (42.3) 6 (23.0)
3.5 4 (15.4) 10 (38.5)
Vitamin D3 supplement 0.272
Yes 3 (11.5) 6 (23.1)
Hepatitis marker 0.449
HBV 2 (7.7) 3 (11.5)
HCV 0 (0) 2 (7.7)
HBV & HCV 0 (0) 1 (3.8)
Baseline
Phosphorus 7.48 ± 1.47 7.36 ± 2.18 0.809
Calcium 9.10 ± 1.09 9.78 ± 0.74 0.012‡
Calcium-phosphorus product 68.51 ± 18.01 80.01 ± 38.21 0.167
iPTH 266.24 ± 205.18 436.86 ± 533.79 0.145
Albumin 4.15 ± 0.32 5.11 ± 5.02 0.332
Alanine transaminase 14.96 ± 7.32 17.56 ± 14.28 0.407
Alkaline phosphatase 148.27 ± 59.70 199.52 ± 99.49 0.028‡
*Data presented as n (%) or mean ± standard deviation for continuous variables; †continuous variables were compared using the stu-
dent’s two-tailed t test; qualitative variables were compared using c2 test; ‡p < 0.05. ESRD = end-stage renal disease; HBV = hepatitis B
virus; HCV = hepatitis C virus; iPTH = intact parathyroid hormone; PCKD = polycystic kidney disease.
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(3 patients, 11.5%), and hyperkalemia (3 patients,
11.5%) (Table 2). The only statistically signifi-
cant treatment difference in AEs was regarding
constipation, with a higher incidence occurring
in the calcium acetate group (p = 0.009).
Serum phosphorus, serum calcium, serum
calcium-phosphorus product, and serum
iPTH levels
There was no difference between the sevelamer
and calcium acetate treatment groups at the end
of the study with regards to the control of serum
phosphorus. Analysis of the results within treat-
ment groups showed that both groups had statis-
tically significant decreases in serum phosphorus
levels from baseline to each specific post treat-
ment time point (p < 0.001; Figure 2A). Over the
8-week treatment period, one patient (3.7%) had
hypercalcemic events during sevelamer treatment
and three patients (12.0%) during calcium ac-
etate treatment. Elevation of serum calcium lev-
els were found only in the calcium acetate group,
but not the sevelamer group (Figure 2B). By the
end of the treatment, the mean change in calcium-
phosphorus product over the 8-week period 
was −19.84 mg2/dL2 (p<0.001) for sevelamer treat-
ment and −15.83 mg2/dL2 (p< 0.001) for calcium
acetate treatment. However, there was no treat-
ment difference in the serum calcium-phosphorus
product between the two groups at the end of the
Patients randomized
(n = 52)
Randomized 1:1
Sevelamer
(n = 26)
Sevelamer
(n = 26)
Completed
(n = 23)
Completed
(n = 20)
Calcium acetate
(n = 26)
Calcium acetate
(n = 26)
Randomization
period
Washout
period
Treatment
period
Dropout (n = 6)
Constipation = 4
GI upset = 1
Nausea = 1
Dropout (n = 3)
Tarry stool = 1
UGI bleeding = 1
Severe itching = 1
Week −2
Week 0
Week 8
Figure 1. Flow diagram of trial.
Table 2. Adverse events during the trial*
Calcium 
Sevelamer p†
acetate
Gastrointestinal 
system
Constipation 6 (23.1) 0 (0) 0.009*
Diarrhea 1 (3.8) 1 (3.8) 1.000
Flatulence 1 (3.8) 4 (15.4) 0.158
Upset 2 (7.7) 2 (7.7) 1.000
Melaena 0 (0) 1 (3.8) 0.313
Nausea 3 (11.5) 0 (0) 0.074
Bleeding 0 (0) 1 (3.8) 0.313
Electrolyte
Hyperkalaemia 3 (11.5) 1 (3.8) 0.298
Nervous system
Increased activity 1 (3.8) 0 (0) 0.313
Skin
Pruritus 0 (0) 1 (3.8) 0.313
*Data presented as n (%); †Fisher’s exact test; ‡p < 0.05.
Y.F. Lin, et al
668 J Formos Med Assoc | 2010 • Vol 109 • No 9
study (Figure 2C). There was also no treatment
difference in the iPTH level change between the
two groups at the end of the study (p = 0.103;
Figure 2D). Sevelamer had similar effects to cal-
cium acetate in the changes of serum calcium,
phosphorus, and calcium-phosphorus product
as stratified by the baseline serum iPTH, except
that the sevelamer significantly decreased serum
phosphorus and calcium-phosphorus product in
those with baseline iPTH higher than 300 pg/mL,
while calcium acetate lowered both in those with
baseline iPTH < 150 pg/mL (Table 3).
Serum iPTH changes according to the initial
iPTH level
Patients under treatment were stratified into sub-
groups according to their baseline iPTH levels
(< 150, 150–300, > 300 pg/mL). Among the pa-
tients with baseline serum iPTH higher than 300
pg/mL, serum iPTH levels decreased after 8 weeks
of sevelamer treatment. However, among patients
with baseline serum iPTH lower than 150 pg/mL,
a significant decrease of serum iPTH level was
noted at the end of the study in the calcium 
acetate group but no such decrease was found 
in the sevelamer group (Figure 3).
Serum ALP level and relationship to
sevelamer dosage
The change of serum ALP levels in both groups
as stratified by the baseline serum iPTH level is
presented in Table 3, which shows that sevelamer
increased the serum ALP level significantly in those
with baseline iPTH < 150 pg/mL and > 300 pg/mL.
The serum ALP level began to increase gradually
and significantly at week 4, week 6, and week 8,
with an increment of 41.75 U/L after 8 weeks of
treatment in the sevelamer group, but this did not
show in the calcium acetate group (Figure 4A). The
serum ALP level was also correlated to the dosage
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weeks of treatment with sevelamer or calcium acetate. iPTH = intact parathyroid hormone.
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of sevelamer (r = 0.246, p = 0.013, Figure 4B).
Furthermore, serum ALP increased under seve-
lamer treatment across different baseline serum
iPTH levels (< 150 or > 150 pg/mL). Such serum
ALP changes were not found in the calcium acetate
group (Figures 4C and 4D).
Discussion
This study shows that sevelamer has similar effects
to calcium acetate on the reduction of serum phos-
phorus and calcium-phosphorus product, but
with fewer hypercalcemic episodes during treat-
ment. In particular, the iPTH level is plausibly
maintained or enhanced and bone turnover rate,
represented by ALP, is improved under sevelamer
treatment, especially in the relative hypoparathy-
roidism group. Thus, the use of sevelamer in hy-
perphosphatemia can avoid the risk of adynamic
bone and is helpful for low turnover bone disease.
We further found that the enhancement of serum
ALP by sevelamer was dose-related. Therefore,
sevelamer has additional beneficial effects that
improve low bone turnover disorders in patients
maintained on HD.
Epidemiologic studies have shown strong in-
dependent correlations between the risk of death
and either hyperphosphatemia or a high calcium-
phosphorus product.19,20 There is growing evi-
dence that hyperphosphatemia, hypercalcemia
and calcium load might play a major role in the
progression of vascular calcification in patients un-
dergoing dialysis.21 Recent studies also noted that
dialysis patients have a high rate of peripheral and
coronary vascular calcification and cardiac valvu-
lar calcification.6,22−25 Ingestion of high-dosage
calcium salt results in elevated serum calcium
concentrations, which in turn is associated with
excessive suppression of parathyroid hormone
and an increased frequency of adynamic bone
Table 3. Changes of serum calcium, phosphorus, calcium-phosphorus product, and alkaline phosphatase
levels stratified by baseline serum iPTH*
Calcium acetate Sevelamer
iPTH (pg/mL)
Baseline Week 8 p† Baseline Week 8 p†
P < 150 7.46 ± 1.06 5.26 ± 1.38 < 0.001‡ 6.59 ± 1.97 5.28 ± 0.65 0.125
150–300 7.95 ± 2.01 6.33 ± 0.86 0.059 8.55 ± 3.38 5.65 ± 1.21 0.110
> 300 7.43 ± 1.56 5.60 ± 1.82 0.209 8.38 ± 1.53 5.86 ± 1.43 0.002‡
Ca < 150 8.91 ± 1.32 9.23 ± 0.80 0.479 9.67 ± 0.78 9.65 ± 0.50 0.943
150–300 9.31 ± 1.40 10.26 ± 0.96 0.167 10.28 ± 0.64 10.34 ± 0.79 0.891
> 300 9.04 ± 0.83 9.61 ± 0.53 0.143 9.95 ± 0.69 9.50 ± 0.61 0.124
Ca-P < 150 66.89 ± 16.12 48.55 ± 13.71 0.011‡ 88.90 ± 60.02 50.95 ± 6.90 0.108
150–300 74.85 ± 26.94 65.24 ± 12.15 0.362 89.20 ± 39.63 58.69 ± 13.72 0.159
> 300 66.53 ± 10.22 53.76 ± 16.84 0.267 83.54 ± 16.68 56.17 ± 16.57 0.004‡
ALP < 150 124.00 ± 25.83 131.88 ± 31.15 0.468 174.88 ± 98.13 218.25 ± 122.60 0.031‡
150–300 129.67 ± 20.26 139.67 ± 36.14 0.507 154.00 ± 43.98 163.00 ± 37.60 0.706
> 300 181.83 ± 97.95 223.67 ± 172.44 0.246 242.00 ± 98.66 322.00 ± 139.92 0.004‡
*Data presented as mean ± standard deviation; †Wilcoxon matched-pairs signed ranks test; ‡p < 0.05. ALP = Alkaline phosphatase;
Ca = calcium; iPTH = intact parathyroid hormone; P = phosphorus.
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disease.26,27 In this study, we analyzed the results
on the basis of baseline iPTH levels to assess the
changes of bone metabolic bone markers, in-
cluding serum iPTH and ALP induced by calcium
acetate and sevelamer. We found that sevelamer
is as efficient as calcium acetate in lowering hyper-
phosphatemia without the side effects of calcium
loading. Calcium loading may increase the
chances of adynamic bone disease.
Adynamic bone disease is associated with a
decreased ability of the bone to buffer serum cal-
cium fluctuations, leading to increased chances 
of sustained hypercalcemia and a higher risk of
extraosseous calcifications.28 Assessment using
ultrasound found that patients with low iPTH have
a greater extent of calcified arteries.29 Dialysis pa-
tients with low iPTH levels also have a tendency
for higher incidence of hip fractures and increased
mortality.30 Thus, low bone turnover might lead to
the development of vascular calcification, which
is associated with cardiovascular disease and is
known to cause mortality and morbidity in dial-
ysis patients. In this study, among the patients with
baseline serum iPTH lower than 150 pg/mL, serum
iPTH levels were decreased significantly by calcium
acetate. Once adynamic bone disease is present,
attempts to further suppress parathyroid hormone
by any calcium load should be avoided.31,32 In
contrast, sevelamer did not decrease the iPTH
level in these patients and for this reason seve-
lamer seems to be a better choice while treating
dialysis patients with hyperphosphatemia and
hypoparathyroidism.
ALP, an enzyme synthesized by osteoblasts, can
be used as an index of bone formation. Increases
in ALP were found in patients with baseline
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300
250
200
150
100
Se
ru
m
 a
lk
al
in
e 
ph
os
ph
at
as
e 
(U
/L
)
−2 0 2 4
Week
6 8
400
300
200
100
0
Se
ru
m
 a
lk
al
in
e 
ph
os
ph
at
as
e 
(U
/L
)
Se
ru
m
 a
lk
al
in
e 
ph
os
ph
at
as
e 
(U
/L
)
Baseline Week 8 Baseline Week 8
Calcium acetate Sevelamer
p = 0.240 p = 0.013
Baseline serum iPTH > 150 pg/mL
400
300
200
100
0
Baseline Week 8 Baseline Week 8
Calcium acetate Sevelamer
Baseline serum iPTH < 150 pg/mL
p = 0.468 p = 0.031
600
400
200
0
Se
ru
m
 a
lk
al
in
e 
ph
os
ph
at
as
e 
(U
/L
)
0 100 200
Sevelamer dose (mg/kg/day)
300
r = 0.246
p = 0.013p = 0.014
A B
C D
Figure 4. (A) Serum alkaline phosphatase changes during 10 weeks of treatment with sevelamer or calcium acetate. 
(B) Correlations of sevelamer dose and serum alkaline phosphatase during the treatment. (C and D) Changes of serum
alkaline phosphatase by serum iPTH level before and after the treatment. Data in each subgroup were compared using
the Wilcoxon matched-pairs signed ranks test.
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iPTH < 150 pg/mL or > 300 pg/mL after sevelamer
treatment. For these cases, sevelamer might have
beneficial effects in helping to improve the low
bone turnover status, especially in those with low
serum iPTH level. This notion was supported by
recent work from Iwata et al in Japanese dialysis
patients.33 Furthermore, animal model studies
have shown that sevelamer prevented develop-
ment of renal osteodystrophy as it increased os-
teoblast function and bone formation rates.34
Recent bone biopsy results from dialysis patients
showed that bone formation was significantly in-
creased with sevelamer, which was associated with
improved trabecular architecture.35 However, the
inexorable nature of adynamic bone disease means
that any improvements in bone histology occur
very slowly, and therefore changes in biochemi-
cal parameters may estimate improvements in
bone histology. Thus, changes in ALP might rep-
resent the status of bone health and substitute
bone biopsy as an alternative method for the eval-
uation of bone formation changes. Remarkably, in
our study we further found that, to our surprise,
the increase in serum ALP due to the action of
sevelamer was related to dose. Sevelamer increased
serum ALP levels in patients with baseline iPTH
> 300 pg/mL. Thus, sevelamer might also activate
bone turnover in patients with hyperparathy-
roidism who require a high dosage of sevelamer
to effectively control serum phosphorus levels.
This finding indicates that sevelamer should be
used with caution when treating patients with
hyperparathyroidism.
There were some limitations to the present
study. First, a bone biopsy was not performed in
our study due to its invasive nature. However, ac-
cording to the K-DOQI guideline 2.2,36 it is not
necessary to perform a bone biopsy except in pa-
tients with fractures when iPTH levels are between
100 and 500 pg/mL with coexisting clinical condi-
tions suggesting renal osteodystrophy or suspected
aluminum bone disease. Consequently, serum
ALP and iPTH levels were used in this study to
investigate comprehensive changes of bone me-
tabolism.37,38 Second, the sample size and treat-
ment duration were limited. Our timeframe was
evidently not long enough to assess the effects of
sevelamer or calcium acetate on the rate of bone
turnover by bone pathology. For this, we await
randomized, well-designed and long-term clini-
cal trials with large sample groups of patients to
accurately measure the change of bone turnover
status and to clarify the possible beneficial effects
of sevelamer in chronic HD patients.
This preliminary study indicated that sevelamer
could reduce serum phosphorus in HD patients
with less hypercalcemia. Sevelamer also had ben-
eficial effects in chronic HD patients with low
turnover bone disease. The pleiotropic effect of
sevelamer may also help protect bone health and
prevent chronic HD patients from cardiovascular
morbidity and mortality. These results may also
enable clinicians to customize the treatment of
hyperphosphatemia in chronic HD patients with
regards to their bone turnover status.
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